{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"43","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Time to Progression (TTP): Time from start of therapy to meeting the definition of Progressive Disease (PD).\n\nPD: 25% increase compared to the lowest value of:\n\n* Serum MP (absolute increase at least ≥ 0.5 g/dl)\n* Or: Urine MP (absolute increase at least \\> 200 mg/24h)\n* Or: for patients without measurable MP, Serum Free Light Chain test: the difference between involved and uninvolved FLC levels (absolute increase at least \\>100 mg/L)","dispersionType":"Full Range","groups":[{"description":"Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.\n\nlenalidomide: Given PO","id":"OG000","title":"Treatment (Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"Patients who developed Progressive Disease while on lenalidomide treatment","reportingStatus":"POSTED","timeFrame":"Up to 9 years","title":"TTP","type":"SECONDARY","unitOfMeasure":"Months"}